Global Blood Therapeutics
181 Oyster Point Blvd
South San Francisco
California
94080
United States
Website: http://www.gbt.com/
Email: info@gbt.com
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
231 articles with Global Blood Therapeutics
-
GBT Announces Participation at the 4th Annual Evercore ISI HealthCONx Conference
11/24/2021
Global Blood Therapeutics, Inc. today announced that it will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021, at 11:45 a.m. ET.
-
GBT Announces Participation in Upcoming Investor Conferences - Nov 12, 2021
11/12/2021
Global Blood Therapeutics, Inc. announced that it will participate in a virtual fireside chat at the Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17, 2021, at 2:00 p.m. ET.
-
GBT Announces New Employment Inducement Grants - Nov 08, 2021
11/8/2021
Global Blood Therapeutics, Inc. announced that on November 1, 2021, the compensation committee of GBT’s board of directors granted eight new employees restricted stock units for an aggregate of 16,350 shares of the company’s common stock.
-
GBT Reports Third Quarter 2021 Financial Results
11/4/2021
Global Blood Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2021 and recent business progress.
-
GBT Announces Six Data Presentations on Sickle Cell Disease at Upcoming 63rd American Society of Hematology (ASH) Annual Meeting & Exposition
11/4/2021
Global Blood Therapeutics, Inc. announced that six abstracts related to its sickle cell disease programs, including data from the growing body of real-world evidence on Oxbryta® tablets and new data on GBT’s pipeline, will be presented at the 63rd American Society of Hematology Annual Meeting & Exposition.
-
GBT to Announce Third Quarter 2021 Financial Results on Thursday, November 4
10/28/2021
Global Blood Therapeutics, Inc. announced that it will report third quarter 2021 financial results on Thursday, November 4, 2021, after U.S. financial markets close.
-
GBT Announces New Employment Inducement Grants - Oct 07, 2021
10/7/2021
Global Blood Therapeutics, Inc. announced that on October 1, 2021, the compensation committee of GBT’s board of directors granted 22 new employees restricted stock units for an aggregate of 54,750 shares of the company’s common stock.
-
GBT Announces Participation at the Cantor Global Healthcare Conference
9/20/2021
Global Blood Therapeutics, Inc. today announced that it will participate in a virtual fireside chat at the Cantor Global Healthcare Conference on Monday, September 27, 2021, at 2:40 p.m. ET.
-
GBT Announces New Employment Inducement Grants - Sep 09, 2021
9/9/2021
Global Blood Therapeutics, Inc. announced that on September 1, 2021, the compensation committee of GBT’s board of directors granted 20 new employees options to purchase an aggregate of 49,600 shares of the company’s common stock with a per share exercise price of $29.85 and restricted stock units for an aggregate of 79,910 shares of the company’s common stock.
-
GBT and Sickle Cell Disease Association of America to Host 10th Annual Sickle Cell Disease (SCD) Therapeutics Conference Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure to deliver keynote
9/8/2021
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the 10th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Wednesday, September 15th.
-
U.S. FDA Accepts for Priority Review Supplemental New Drug Application for Oxbryta® (voxelotor) for the Treatment of Sickle Cell Disease in Children Ages 4 to 11
9/7/2021
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the company’s supplemental New Drug Application (sNDA) seeking accelerated approval for Oxbryta®
-
GBT Announces Participation in Upcoming Investor Conferences in September 2021
9/2/2021
Global Blood Therapeutics, Inc. announced that it will participate in virtual fireside chats at the following investor conferences.
-
GBT Announces New Employment Inducement Grants - Aug 12, 2021
8/12/2021
Global Blood Therapeutics, Inc. announced that on August 1, 2021, the compensation committee of GBT’s board of directors granted 12 new employees restricted stock units for an aggregate of 33,050 shares of the company’s common stock.
-
GBT Announces Participation at the Wedbush PacGrow Healthcare Conference
8/4/2021
Global Blood Therapeutics, Inc. announced that it will participate in a virtual fireside chat at the Wedbush PacGrow Healthcare Conference on Wednesday, August 11, 2021, at 2:20 p.m. ET.
-
GBT Reports Second Quarter 2021 Financial Results
8/3/2021
Global Blood Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2021 and recent business progress.
-
GBT to Announce Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
7/27/2021
Global Blood Therapeutics, Inc. announced that it will report second quarter 2021 financial results on Tuesday, August 3, 2021, after U.S. financial markets close.
-
GBT Provides Regulatory and Pipeline Updates in Sickle Cell Disease (SCD)
7/22/2021
Global Blood Therapeutics, Inc. announced updates across several of its development programs in sickle cell disease.
-
The Biotech Bay region is home to 3,418 life sciences companies, and 96,574 employees making an average of $151,076.
-
GBT Announces New Employment Inducement Grants - July 09, 2021
7/9/2021
Global Blood Therapeutics, Inc. announced that on July 1, 2021, the compensation committee of GBT’s board of directors granted 23 new employees options to purchase an aggregate of 9,600 shares of the company’s common stock with a per share exercise price of $37.34 and restricted stock units for an aggregate of 94,320 shares of the company’s common stock.
-
GBT Awards $450,000 in ACCEL Grants to Improve Access to Care in Sickle Cell Disease
6/15/2021
Global Blood Therapeutics, Inc. has awarded approximately $450,000 to U.S. community-based organizations and institutions as part of the company’s 2021 Access to Excellent Care for Sickle Cell Patients (ACCEL) Grant Program.